What is the current valuation of the Therapeutic Proteins and Oral Vaccines Market?

The market valuation was 222.83 USD Billion in 2024. Read More

What is the projected market size for the Therapeutic Proteins and Oral Vaccines Market by 2035?

The projected valuation for 2035 is 554.0 USD Billion. Read More

What is the expected CAGR for the Therapeutic Proteins and Oral Vaccines Market during the forecast period 2025 - 2035?

The expected CAGR during this period is 8.63%. Read More

Which therapeutic class segment holds the highest market value in the Therapeutic Proteins sector?

The Antibodies segment holds the highest market value, with a range from 66.85 to 165.0 USD Billion. Read More

What are the key players in the Therapeutic Proteins and Oral Vaccines Market?

Key players include AbbVie, Amgen, Bristol-Myers Squibb, Johnson & Johnson, and Merck & Co. Read More

Which vaccine type is projected to have the highest market value by 2035?

The Subunit vaccine type is projected to reach a market value between 60.0 and 130.0 USD Billion. Read More

What disease indication segment is expected to show significant growth in the Therapeutic Proteins and Oral Vaccines Market?

The Infectious diseases segment is expected to grow significantly, with a projected range of 60.0 to 150.0 USD Billion. Read More

How does the Oral route of administration compare to other routes in terms of market value?

The Oral route is projected to have the highest market value, ranging from 80.0 to 200.0 USD Billion. Read More

What is the market value range for the Enzymes segment in the Therapeutic Proteins category?

The Enzymes segment has a market value range from 33.42 to 83.0 USD Billion. Read More

Which company is likely to lead the market in terms of innovation in therapeutic proteins?

Companies like Pfizer and Roche are likely to lead in innovation within the therapeutic proteins sector. Read More

Therapeutic Proteins Oral Vaccines Market

ID: MRFR/Pharma/26212-HCR

100 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Therapeutic Proteins And Oral Vaccines Market Research Report By Therapeutic Class (Antibodies, Enzymes, Hormones, Growth factors, Polypeptides), By Vaccine Type (Live attenuated, Inactivated, Toxoid, Subunit, Conjugate), By Disease Indication (Cancer, Cardiovascular diseases, Autoimmune diseases, Infectious diseases, Neurological disorders), By Route of Administration (Intravenous, Subcutaneous, Intramuscular, Oral, Topical) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Therapeutic Proteins Oral Vaccines Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Therapeutic Class (USD Billion)
4.1.1 Antibodies
4.1.2 Enzymes
4.1.3 Hormones
4.1.4 Growth factors
4.1.5 Polypeptides
4.2 Healthcare, BY Vaccine Type (USD Billion)
4.2.1 Live attenuated
4.2.2 Inactivated
4.2.3 Toxoid
4.2.4 Subunit
4.2.5 Conjugate
4.3 Healthcare, BY Disease Indication (USD Billion)
4.3.1 Cancer
4.3.2 Cardiovascular diseases
4.3.3 Autoimmune diseases
4.3.4 Infectious diseases
4.3.5 Neurological disorders
4.4 Healthcare, BY Route of Administration (USD Billion)
4.4.1 Intravenous
4.4.2 Subcutaneous
4.4.3 Intramuscular
4.4.4 Oral
4.4.5 Topical
4.5 Healthcare, BY Region (USD Billion)
4.5.1 North America
4.5.1.1 US
4.5.1.2 Canada
4.5.2 Europe
4.5.2.1 Germany
4.5.2.2 UK
4.5.2.3 France
4.5.2.4 Russia
4.5.2.5 Italy
4.5.2.6 Spain
4.5.2.7 Rest of Europe
4.5.3 APAC
4.5.3.1 China
4.5.3.2 India
4.5.3.3 Japan
4.5.3.4 South Korea
4.5.3.5 Malaysia
4.5.3.6 Thailand
4.5.3.7 Indonesia
4.5.3.8 Rest of APAC
4.5.4 South America
4.5.4.1 Brazil
4.5.4.2 Mexico
4.5.4.3 Argentina
4.5.4.4 Rest of South America
4.5.5 MEA
4.5.5.1 GCC Countries
4.5.5.2 South Africa
4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 AbbVie (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Amgen (US)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Bristol-Myers Squibb (US)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Johnson & Johnson (US)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Merck & Co. (US)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Novartis (CH)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Pfizer (US)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Roche (CH)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 Sanofi (FR)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.2.10 GSK (GB)
5.2.10.1 Financial Overview
5.2.10.2 Products Offered
5.2.10.3 Key Developments
5.2.10.4 SWOT Analysis
5.2.10.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY THERAPEUTIC CLASS
6.4 US MARKET ANALYSIS BY VACCINE TYPE
6.5 US MARKET ANALYSIS BY DISEASE INDICATION
6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.7 CANADA MARKET ANALYSIS BY THERAPEUTIC CLASS
6.8 CANADA MARKET ANALYSIS BY VACCINE TYPE
6.9 CANADA MARKET ANALYSIS BY DISEASE INDICATION
6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.11 EUROPE MARKET ANALYSIS
6.12 GERMANY MARKET ANALYSIS BY THERAPEUTIC CLASS
6.13 GERMANY MARKET ANALYSIS BY VACCINE TYPE
6.14 GERMANY MARKET ANALYSIS BY DISEASE INDICATION
6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.16 UK MARKET ANALYSIS BY THERAPEUTIC CLASS
6.17 UK MARKET ANALYSIS BY VACCINE TYPE
6.18 UK MARKET ANALYSIS BY DISEASE INDICATION
6.19 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.20 FRANCE MARKET ANALYSIS BY THERAPEUTIC CLASS
6.21 FRANCE MARKET ANALYSIS BY VACCINE TYPE
6.22 FRANCE MARKET ANALYSIS BY DISEASE INDICATION
6.23 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.24 RUSSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
6.25 RUSSIA MARKET ANALYSIS BY VACCINE TYPE
6.26 RUSSIA MARKET ANALYSIS BY DISEASE INDICATION
6.27 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.28 ITALY MARKET ANALYSIS BY THERAPEUTIC CLASS
6.29 ITALY MARKET ANALYSIS BY VACCINE TYPE
6.30 ITALY MARKET ANALYSIS BY DISEASE INDICATION
6.31 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.32 SPAIN MARKET ANALYSIS BY THERAPEUTIC CLASS
6.33 SPAIN MARKET ANALYSIS BY VACCINE TYPE
6.34 SPAIN MARKET ANALYSIS BY DISEASE INDICATION
6.35 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.36 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC CLASS
6.37 REST OF EUROPE MARKET ANALYSIS BY VACCINE TYPE
6.38 REST OF EUROPE MARKET ANALYSIS BY DISEASE INDICATION
6.39 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.40 APAC MARKET ANALYSIS
6.41 CHINA MARKET ANALYSIS BY THERAPEUTIC CLASS
6.42 CHINA MARKET ANALYSIS BY VACCINE TYPE
6.43 CHINA MARKET ANALYSIS BY DISEASE INDICATION
6.44 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.45 INDIA MARKET ANALYSIS BY THERAPEUTIC CLASS
6.46 INDIA MARKET ANALYSIS BY VACCINE TYPE
6.47 INDIA MARKET ANALYSIS BY DISEASE INDICATION
6.48 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.49 JAPAN MARKET ANALYSIS BY THERAPEUTIC CLASS
6.50 JAPAN MARKET ANALYSIS BY VACCINE TYPE
6.51 JAPAN MARKET ANALYSIS BY DISEASE INDICATION
6.52 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.53 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC CLASS
6.54 SOUTH KOREA MARKET ANALYSIS BY VACCINE TYPE
6.55 SOUTH KOREA MARKET ANALYSIS BY DISEASE INDICATION
6.56 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.57 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
6.58 MALAYSIA MARKET ANALYSIS BY VACCINE TYPE
6.59 MALAYSIA MARKET ANALYSIS BY DISEASE INDICATION
6.60 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.61 THAILAND MARKET ANALYSIS BY THERAPEUTIC CLASS
6.62 THAILAND MARKET ANALYSIS BY VACCINE TYPE
6.63 THAILAND MARKET ANALYSIS BY DISEASE INDICATION
6.64 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.65 INDONESIA MARKET ANALYSIS BY THERAPEUTIC CLASS
6.66 INDONESIA MARKET ANALYSIS BY VACCINE TYPE
6.67 INDONESIA MARKET ANALYSIS BY DISEASE INDICATION
6.68 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.69 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC CLASS
6.70 REST OF APAC MARKET ANALYSIS BY VACCINE TYPE
6.71 REST OF APAC MARKET ANALYSIS BY DISEASE INDICATION
6.72 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.73 SOUTH AMERICA MARKET ANALYSIS
6.74 BRAZIL MARKET ANALYSIS BY THERAPEUTIC CLASS
6.75 BRAZIL MARKET ANALYSIS BY VACCINE TYPE
6.76 BRAZIL MARKET ANALYSIS BY DISEASE INDICATION
6.77 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.78 MEXICO MARKET ANALYSIS BY THERAPEUTIC CLASS
6.79 MEXICO MARKET ANALYSIS BY VACCINE TYPE
6.80 MEXICO MARKET ANALYSIS BY DISEASE INDICATION
6.81 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.82 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC CLASS
6.83 ARGENTINA MARKET ANALYSIS BY VACCINE TYPE
6.84 ARGENTINA MARKET ANALYSIS BY DISEASE INDICATION
6.85 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC CLASS
6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY VACCINE TYPE
6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE INDICATION
6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.90 MEA MARKET ANALYSIS
6.91 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC CLASS
6.92 GCC COUNTRIES MARKET ANALYSIS BY VACCINE TYPE
6.93 GCC COUNTRIES MARKET ANALYSIS BY DISEASE INDICATION
6.94 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.95 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC CLASS
6.96 SOUTH AFRICA MARKET ANALYSIS BY VACCINE TYPE
6.97 SOUTH AFRICA MARKET ANALYSIS BY DISEASE INDICATION
6.98 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.99 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC CLASS
6.100 REST OF MEA MARKET ANALYSIS BY VACCINE TYPE
6.101 REST OF MEA MARKET ANALYSIS BY DISEASE INDICATION
6.102 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.103 KEY BUYING CRITERIA OF HEALTHCARE
6.104 RESEARCH PROCESS OF MRFR
6.105 DRO ANALYSIS OF HEALTHCARE
6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
6.109 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 (% SHARE)
6.110 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 TO 2035 (USD Billion)
6.111 HEALTHCARE, BY VACCINE TYPE, 2024 (% SHARE)
6.112 HEALTHCARE, BY VACCINE TYPE, 2024 TO 2035 (USD Billion)
6.113 HEALTHCARE, BY DISEASE INDICATION, 2024 (% SHARE)
6.114 HEALTHCARE, BY DISEASE INDICATION, 2024 TO 2035 (USD Billion)
6.115 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
6.116 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.2.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.2.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.3.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.3.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.4.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.4.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.5.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.5.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.6.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.6.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.7.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.7.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.8.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.8.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.9.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.9.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.10.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.10.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.11.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.11.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.12.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.12.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.13.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.13.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.14.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.14.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.15.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.15.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.16.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.16.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.17.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.17.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.18.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.18.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.19.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.19.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.20.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.20.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.21.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.21.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.22.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.22.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.23.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.23.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.24.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.24.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.25.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.25.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.26.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.26.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.27.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.27.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.28.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.28.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.29.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.29.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
7.30.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
7.30.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Therapeutic Class (USD Billion, 2025-2035)

Antibodies
Enzymes
Hormones
Growth factors
Polypeptides

Healthcare By Vaccine Type (USD Billion, 2025-2035)

Live attenuated
Inactivated
Toxoid
Subunit
Conjugate

Healthcare By Disease Indication (USD Billion, 2025-2035)

Cancer
Cardiovascular diseases
Autoimmune diseases
Infectious diseases
Neurological disorders

Healthcare By Route of Administration (USD Billion, 2025-2035)

Intravenous
Subcutaneous
Intramuscular
Oral
Topical

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓